On November 20, the “2023 China Industrial Transfer and Development Docking Event (Chongqing)” opened. The reporter learned from a special docking event on the biomedicine and medical equipment industries that by the end of the “14th Five-Year Plan”, the scale of the city’s biomedicine industry will strive to exceed 200 billion yuan.
The biopharmaceutical industry is one of the six innovative and advantageous industrial clusters in the “33618” modern manufacturing cluster system that Chongqing is building.
The person in charge of the Municipal Economic and Information Commission introduced at the docking event that in recent years, Chongqing has vigorously developed biopharmaceutical industry clusters worth RMB 100 billion and has accelerated the construction of a “1+5+N” pharmaceutical industry system. Among them, a national biopharmaceutical industry cluster will be built with Chongqing International Biocity as the core; Liangjiang New District, Western Science City, Chongqing High-tech Zone, Changshou Economic and Technological Development Zone, Fuling District and Dadukou District as the backbone to accelerate the industry Gather and develop industrial bases; encourage other industrial parks with suitable conditions to build characteristic pharmaceutical industry parks according to their own characteristics.
At present, there are more than 180 pharmaceutical manufacturers and more than 370 medical device manufacturers in Chongqing’s pharmaceutical industry; there are more than 200 regulated enterprises in the pharmaceutical industry, of which nearly 60 have an output value of over 100 million; “little giants” and professional experts in the pharmaceutical industry There are 121 new Jingte companies and 15 listed companies. Among them, Zhifei Biotechnology has a market value of more than 150 billion yuan.
In the field of innovation, Chongqing’s pharmaceutical industry has performed well. Currently, Chongqing has “first-of-its-kind” products such as the country’s first approved artificial heart and the world’s first Haifu knife focused ultrasound tumor treatment system. As of now, the city has more than 3,600 drug approvals and nearly 4,000 medical device registrations and filings; more than 30 innovative drug projects have entered the clinical trial stage, including monoclonal antibodies, insulin, tumor vaccines, Car-T cells, etc.
According to the plan, by the end of the “14th Five-Year Plan”, the scale of Chongqing’s biopharmaceutical industry will strive to exceed 200 billion yuan, and it will cultivate 3 enterprises with an output value of 10 billion and 5 enterprises with an output value of 5 billion.
At the special docking event for the biomedicine and medical equipment industries that day, about 200 people from relevant government departments, national industry associations, and foreign merchants and enterprises gathered together to seek common development.
The person in charge of the Municipal Economic and Information Commission said that Chongqing hopes to use this special docking event as an opportunity to increase the introduction of key areas such as antibodies, recombinant proteins and peptide drugs, and vaccines, and to develop development in areas such as in vitro diagnostics, smart equipment, and high-value consumables. The medical device industry provides a development platform for companies that produce first-line drugs for acute infectious diseases, malignant tumors, cardiovascular and cerebrovascular diseases and other major diseases, vigorously undertakes the transfer of the API industry, and strengthens specialty APIs and excipients.
Hualong.com chief reporter Lian Xiao/Wen Chenyang/Photo
